GD-SIROLIMUS 1 MG
SIROLIMUS : 1 MG · DIN 02373394 · GENMED A DIVISION OF PFIZER CANADA ULC
Health Canada status: APPROVED
What is GD-SIROLIMUS?
GD-SIROLIMUS 1 MG contains SIROLIMUS : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02373394, held by GENMED A DIVISION OF PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 04-Oct-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02373394 |
|---|---|
| Brand name | GD-SIROLIMUS |
| Generic / active ingredient | SIROLIMUS : 1 MG |
| Manufacturer | GENMED A DIVISION OF PFIZER CANADA ULC |
| Strength | 1 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AH01 SIROLIMUS |
| AHFS class | 90:28.24.92 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 04-Oct-2011 |
What can be used instead?
Other Canadian products sharing ATC code L04AH01 SIROLIMUS. 2 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| RAPAMUNE | 1 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02247111 |
| RAPAMUNE | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02243237 |
| GD-SIROLIMUS | 1 MG | SOLUTION | GENMED A DIVISION OF PFIZER CANADA ULC | APPROVED | DIN 02373386 |
| GD-SIROLIMUS | 2 MG | TABLET | GENMED A DIVISION OF PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02373408 |
| GD-SIROLIMUS | 5 MG | TABLET | GENMED A DIVISION OF PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02373416 |
| RAPAMUNE | 2 MG | TABLET | PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02270617 |
| RAPAMUNE | 5 MG | TABLET | PFIZER CANADA ULC | CANCELLED PRE MARKET | DIN 02270684 |
Who else supplies SIROLIMUS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SIROLIMUS appears in 83 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.